ANXA1 and ischemic stroke: However, the present study revealed that Tat‐SIRT5‐CTM targets the SIRT5‐ANXA1 complex, resulting in SIRT5 degradation via the lysosomal pathway, which eventually alleviates microglia‐induced neuroinflammation and neuronal injury following ischemic stroke.20